Onkologie. 2012:6(2):71-73

Primary surgical treatment in ovarian cancer

Jaroslav Klát
Porodnicko-gynekologická klinika FN Ostrava

Completeness of the primary surgical staging in early-stage ovarian cancer has a strong impact on the prognosis and it could distinguish

between low and high risk patients for the recurrence of the disease. The standard treatment of advanced-stage ovarian carcinoma

includes radical cytoreductive surgery which aims at removing a visible tumor followed by platinum-based chemotherapy. Complete

resection is achieved when no macroscopically visible residual tumor is left. The prognostic value of complete debulking on overall

survival has been confirmed. In patients presenting with extensive metastatic tumor spread, complete tumor resection may require

extensive upper abdominal surgery, including procedures such as diaphragm resection or peritonectomy, splenectomy, or partial liver

resection. These extended surgical procedures require a multidisciplinary approach. The patients being treated in onco-gynecological

centers have a higher chance to achieve complete tumor resection.

Keywords: ovarian cancer, primary surgical treatment, residual tumor

Published: April 23, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Klát J. Primary surgical treatment in ovarian cancer. Onkologie. 2012;6(2):71-73.
Download citation

References

  1. Bois DA, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd Inrenational Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16(Suppl 8): 7-12. Go to original source... Go to PubMed...
  2. Bois DA, Rochon J, Lamparter C, and for AGO Organkommission PFisterer J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynec Cancer 2005; 15: 183-191. Go to original source... Go to PubMed...
  3. Goff BA, Matthews BJ, Larson EH, et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 2007; 109: 2031-2042. Go to original source... Go to PubMed...
  4. Griffiths CT. Surgical nresection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42: 101-104. Go to PubMed...
  5. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-1259. Go to original source... Go to PubMed...
  6. Bois DA, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 2009; 15: 1234-1244. Go to original source... Go to PubMed...
  7. Schueler JA, Trimbos JB, Hermans J, Fleuren GJ. The yield of surgical staging in presumed early stage ovarian cancer; benefits or doubts? Int J Gynecol Cancer 1998; 8: 95-102. Go to original source...
  8. Trimbos JB, Parmar M, Guthrie D, et al. International Collaborative Study Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm Trial: Two parallel randomized phasa III trials in adjuvant chemotherapy in patients with earlystage ovarian cancer. Natl Cancer Inst 2003; 95: 105-112. Go to original source... Go to PubMed...
  9. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003; 95: 113-125. Go to original source... Go to PubMed...
  10. Munoz-Casares FC, Rufian S, Rubio MJ, et al. Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposal. Clin Transl Oncol 2007; 9: 652-662. Go to original source... Go to PubMed...
  11. Benedetti Panici P, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomized clinical trial. J Natl Cancer Inst 2005; 97: 560-566. Go to original source... Go to PubMed...
  12. Winter WE, Maxwell L, Tian Ch, et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecology Oncology Group Study. J Clin Oncol 2007; 25: 3621-3627. Go to original source... Go to PubMed...
  13. Aletti GA, Dowdy SC, Gostout BS, et al. Aggresive surgical effort and improved survival in advancede-stage ovarian cancer. Obstet Gynecol 2006; 107: 77-85. Go to original source... Go to PubMed...
  14. Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012; 124: 10-14. Go to original source... Go to PubMed...
  15. Kommoss S, Rochon J, Harter P, et al. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol 2010; 19: 279-286. Go to original source... Go to PubMed...
  16. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Eng J Med 2010; 363: 943-953. Go to original source... Go to PubMed...
  17. Rauh-Hain JA, Rodriguez N, Growdon W, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol 2012; 19: 959-965. Go to original source... Go to PubMed...
  18. Winter WE, Maxwell GL, Tian Ch, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial Ovarian Cancer: A Gynecology Oncology Group Study. J Clin Oncol 2008; 26: 83-89. Go to original source... Go to PubMed...
  19. Wimberger P, Wehling M, Lehman N, et al. Impact of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease. An exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 2010; 17: 1642-1648. Go to original source... Go to PubMed...
  20. Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.G.: Gruppo InterregionaleCollaborativo in Ginecologia Oncologica. Ann Onco 1995; 6: 887-893. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.